GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Cyclically Adjusted Book per Share

MorphoSys AG (XSWX:MOR) Cyclically Adjusted Book per Share : CHF0.00 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

MorphoSys AG's adjusted book value per share for the three months ended in Dec. 2023 was CHF1.354. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CHF0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, MorphoSys AG's average Cyclically Adjusted Book Growth Rate was -2.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of MorphoSys AG was 7.50% per year. The lowest was 3.60% per year. And the median was 6.85% per year.

As of today (2024-05-22), MorphoSys AG's current stock price is CHF102.00. MorphoSys AG's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was CHF0.00. MorphoSys AG's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of MorphoSys AG was 10.72. The lowest was 0.90. And the median was 6.70.


MorphoSys AG Cyclically Adjusted Book per Share Historical Data

The historical data trend for MorphoSys AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Cyclically Adjusted Book per Share Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.22 14.89 45.45 - -

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MorphoSys AG's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, MorphoSys AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Cyclically Adjusted PB Ratio falls into.



MorphoSys AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MorphoSys AG's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.354/123.7729*123.7729
=1.354

Current CPI (Dec. 2023) = 123.7729.

MorphoSys AG Quarterly Data

Book Value per Share CPI Adj_Book
201403 16.365 99.543 20.349
201406 16.413 99.543 20.408
201409 16.191 99.823 20.076
201412 16.130 99.543 20.056
201503 15.913 99.717 19.752
201506 15.361 100.417 18.934
201509 15.710 100.417 19.364
201512 15.063 99.717 18.697
201603 14.816 100.017 18.335
201606 14.285 100.717 17.555
201609 13.789 101.017 16.895
201612 15.532 101.217 18.993
201703 14.949 101.417 18.244
201706 14.715 102.117 17.836
201709 14.622 102.717 17.619
201712 14.396 102.617 17.364
201803 13.682 102.917 16.455
201806 18.319 104.017 21.798
201809 19.020 104.718 22.481
201812 17.463 104.217 20.740
201903 16.706 104.217 19.841
201906 16.367 105.718 19.162
201909 15.259 106.018 17.814
201912 13.580 105.818 15.884
202003 21.700 105.718 25.406
202006 21.496 106.618 24.955
202009 19.685 105.818 23.025
202012 20.499 105.518 24.045
202103 19.586 107.518 22.547
202106 20.060 108.486 22.887
202109 18.992 109.435 21.480
202112 7.463 110.384 8.368
202203 4.248 113.968 4.613
202206 -0.825 115.760 -0.882
202209 0.000 118.818 0.000
202212 4.547 119.345 4.716
202303 2.814 122.402 2.846
202306 0.904 123.140 0.909
202309 0.000 124.195 0.000
202312 1.354 123.773 1.354

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


MorphoSys AG  (XSWX:MOR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of MorphoSys AG was 10.72. The lowest was 0.90. And the median was 6.70.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


MorphoSys AG Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (XSWX:MOR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Cyclically Adjusted Book per Share
Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (XSWX:MOR) Headlines